Pagel Bio: The new generation GLP-1 (CR059) can maintain metabolic intervention effects for several weeks after a single subcutaneous injection in a healthy rhesus monkey model.

2026-04-12 20:28:48

PageBio announces that the company’s next-generation GLP-1 receptor agonist CR059, independently developed based on circular RNA (CircRNA) protein replacement technology combined with an artificial intelligence-assisted molecular design platform, is a candidate product for early clinical validation of the GLP-1 receptor activation mechanism in the phased development strategy of the PB-2309 triple receptor (GLP-1/GIP/GCG) agonist project. It has completed single-dose administration in subjects and obtained one-month human clinical observation results.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.